Five patients had received immunotherapy due to metastatic melanoma treated with the nivolumab/ipilimumab combination, 5 due to non-small cell lung cancer (NSCLC) (3 were treated with anti-PD-1 monotherapy, 1 with anti-PD-L1 monotherapy, and 1 with anti-CTLA-4 monotherapy), and 1 due to small cell lung cancer (SCLC) (treated with anti-PD-1 monotherapy). Here, PDCD1 is linked to non-small cell lung carcinoma.